All Times EDT
As we look to the future of RWE, we will see greater use of RWE to guide clinical guideline development, particularly with regard to populations that are underrepresented in clinical trials. These studies will address treatments benefits as well as risks. There will also be continued efforts to identify drugs that can be repurposed for new uses. Examples will be provided.
Nancy Dreyer is senior vice president and chief scientific officer, emerita for real-world solutions at IQVIA and adjunct professor of epidemiology at The University of North Carolina at Chapel Hill. She is responsible for driving innovation in medical product development and commercialization using passive and/or active collection of real-world data to generate evidence for regulators, clinicians, patients, and payers. A fellow of both the International Society of Pharmacoepidemiology and DIA, she is well-known for her thought leadership. Dreyer has helped advance the use of real-world evidence for regulatory purposes, influencing the content of recent guidelines by regulators in the US, Europe, and China, each of which cite one or more of her publications. Her substantial executive and field experience have helped hone her pragmatic views.